Women’s healthcare company Ava Science has reported positive data from a clinical trial of its Fertility Tracker, a wearable device designed to identify five most fertile days of a woman’s cycle in real-time.
Study data showed that the device was able to detect significant, phase-based shifts in different physiological parameters throughout a woman’s menstrual cycle to determine her fertile window.
To be worn only during sleep, the device tracks pulse rate, breathing rate and temperature, among other physiological parameters.
The company noted that the device captures data on changes in multiple signals throughout the menstrual cycle, analyses them with a deep machine learning algorithm, and informs users.
Apart from identifying fertile days, Ava Fertility Tracker also offers personalised insight on reproductive health and pregnancy.
The Ava sensor bracelet’s clinical study involved more than 200 women and more than 1,000 menstrual cycles.
Changes in various physiological parameters collected by the bracelet during the menstrual cycle were observed to accurately identify the five most fertile days of a woman’s cycle with 89% accuracy.
Results from the trial have been published in Journal of Internet Medical Research.
Study principal investigator Dr Brigitte Leeners said: “For the first time, we are able to demonstrate that tracking several physiological parameters – not just temperature – is important for fertility tracking.
“Ava helps women learn about their fertility and enables individualised, real-time fertility detection that is easy to use.”
Ava Science noted that the device is being further studied in a new large cohort study, comprising multiple sub-studies, at University Hospital of Zurich, Switzerland.
This study will focus on irregular cycles and pregnancy complications.
In addition, the company is planning to report results from the comparison of its approach with a variety of other established period tracking methods based on population statistics.
Launched in the US in July 2016, the Ava bracelet is now available in 36 countries.